Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

820
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
820

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Confocal Multispectral Imaging Using a Common Commercial Device and Application in a Healthy Aging Mouse Model.

Investigative ophthalmology & visual science·2026
Same author

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

iScience·2026
Same author

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

The New England journal of medicine·2026
Same author

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Communications medicine·2026
Same author

Germline polygenic score for prostate cancer aggressiveness.

medRxiv : the preprint server for health sciences·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Nov 11, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate

Ioulia Vardaki1,2, Paul Corn1, Emanuela Gentile1

  • 1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 23, 2021
PubMed
Summary

Exosomes in patient blood may monitor response to Radium-223 treatment for prostate cancer. Combining Radium-223 with immune checkpoint therapy (ICT) improved treatment efficacy in preclinical models.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

5.9K

Related Experiment Videos

Last Updated: Nov 11, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

5.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Radium-223 improves survival in some men with bone metastatic prostate cancer (PCa).
  • Current methods lack markers to monitor Radium-223 treatment response and resistance.
  • Exosomes, key in cell communication, may reflect bone microenvironment changes during Radium-223 therapy.

Purpose of the Study:

  • To investigate exosome molecular profiles for monitoring Radium-223 treatment response in prostate cancer.
  • To compare exosome profiles in patients with favorable versus unfavorable survival outcomes.
  • To explore the potential of exosomal RNA as a biomarker for bone tumor microenvironment (bTME) response.

Main Methods:

  • Exosomal transcriptome analysis was performed on plasma from preclinical PCa models and 25 patients undergoing Radium-223 treatment.
  • Paired baseline and end-of-treatment samples were analyzed using array technology.
  • Data analysis involved fold changes (+2 to -2) and statistical significance (P < 0.05).

Main Results:

  • Radium-223 treatment altered exosomal gene expression in both preclinical models and patients, affecting bone-related and DNA damage repair pathways.
  • Exosomal transcripts identified immune-suppressive molecules, such as PD-L1, associated with poorer survival.
  • Combination therapy of Radium-223 and immune checkpoint therapy (ICT) demonstrated enhanced efficacy in a preclinical model.

Conclusions:

  • RNA profiling of plasma exosomes can serve as a tool to monitor the bone tumor microenvironment (bTME) during Radium-223 treatment.
  • Immune checkpoint therapy (ICT) holds potential for increasing Radium-223 efficacy in prostate cancer treatment.